Cargando…

Association Between Nonselective Beta-Blocker Use and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Without Cirrhosis and Decompensation

Background: Nonselective beta-blockers (NSBBs) can reduce the incidence or mortality of certain types of cancers, and NSBBs exert a protective effect on hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the potential preventive effect of NSBBs has not yet been investigated in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, He-Yun, Lin, Hsiu C., Lin, Hsiu L., Uang, Yow S., Keller, Joseph J., Wang, Li H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777254/ https://www.ncbi.nlm.nih.gov/pubmed/35069216 http://dx.doi.org/10.3389/fphar.2021.805318

Ejemplares similares

Nonselective beta-blocker use is associated with increased hepatic encephalopathy-related readmissions in cirrhosis
por: Fallahzadeh, Mohammad Amin, et al.
Publicado: (2022)

Hemodynamic Evaluation of Nonselective β-Blockers in Patients with Cirrhosis and Refractory Ascites
por: Ferrarese, Alberto, et al.
Publicado: (2018)

Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
por: He, Xinyi, et al.
Publicado: (2023)

Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign
por: Wang, Sheng-Fu, et al.
Publicado: (2020)

Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis?
por: Kim, Tae Wan, et al.
Publicado: (2012)

Nonselective beta-blockers may lead to stage 2 acute kidney injury and waitlist mortality in child class C cirrhosis
por: Lai, Mason, et al.
Publicado: (2023)

Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD
por: Huang, Yueh Lan, et al.
Publicado: (2017)

Association Between Acid-Suppressive Agents’ Use and Risk of Hepatocellular Carcinoma
por: Lin, Hsiu C., et al.
Publicado: (2020)

Exploration on the Effect of Nonselective β-Receptor Blockers (NSBBs) on Hemodynamic Parameters in Complicated Liver Cirrhosis
por: Mao, Gang, et al.
Publicado: (2022)

Retracted: Exploration on the Effect of Nonselective β-Receptor Blockers (NSBBs) on Hemodynamic Parameters in Complicated Liver Cirrhosis
por: International, BioMed Research
Publicado: (2023)

The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients
por: Zampino, Rosa, et al.
Publicado: (2018)

Beta-blockers in liver cirrhosis
por: Giannelli, Valerio, et al.
Publicado: (2014)

The association between nonselective beta-blockers and portal venous thrombosis in cirrhotic patients: More questions on the horizon
por: Bartell, Nicholas, et al.
Publicado: (2018)

Assessment of Haemodynamic Response to Nonselective Beta-Blockers in Portal Hypertension by Phase-Contrast Magnetic Resonance Angiography
por: McDonald, Natasha, et al.
Publicado: (2017)

Nonselective Beta-Blockers for the Efficacious Healing of Ulcerated Infantile Hemangiomas in Unusual Locations of Two Female Infants
por: Poulose, Divya, et al.
Publicado: (2021)

Nonselective beta-adrenoceptor blocker use and risk of Parkinson’s disease: from multiple real-world evidence
por: Feng, Zeying, et al.
Publicado: (2023)

Use of gastric acid–suppressive agents increases the risk of dementia in patients with upper gastrointestinal disease: A population-based retrospective cohort study
por: Lin, Hsiu-Chen, et al.
Publicado: (2021)

Carvedilol Versus Other Nonselective Beta Blockers for Variceal Bleeding Prophylaxis and Death: A Network Meta-analysis
por: Cheung, Ka-Shing, et al.
Publicado: (2023)

Nonlinear Relationship Between Macrocytic Anemia and Decompensated Hepatitis B Virus Associated Cirrhosis: A Population-Based Cross-Sectional Study
por: Zhao, Tian-Yu, et al.
Publicado: (2021)

Association Between Use of Antihyperlipidemic Agents and Chronic Obstructive Pulmonary Disease in Patients with Hyperlipidemia: A Population-Based Retrospective Cohort Study
por: Lei, Yi-Fen, et al.
Publicado: (2020)

Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis
por: Gurbuz, Berivan, et al.
Publicado: (2023)

Association between statin use and the risk of gout in patients with hyperlipidemia: A population-based cohort study
por: Lin, Guan-Ling, et al.
Publicado: (2023)

Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus
por: Kumada, Takashi, et al.
Publicado: (2021)

Treatment of Hepatitis B in Decompensated Liver Cirrhosis
por: Guan, Richard, et al.
Publicado: (2011)

Beta-blockers in cardiac arrhythmias–Clinical pharmacologist’s point of view
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

An evaluation of the effects of nonselective and cardioselective β-blockers on wound healing in Sprague Dawley rats
por: Raut, Sanket B., et al.
Publicado: (2012)

Beta-blockers in cirrhosis: Evidence-based indications and limitations
por: Rodrigues, Susana G., et al.
Publicado: (2019)

Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
por: Sauerbruch, Tilman, et al.
Publicado: (2023)

New Insights into Cardiac and Brain Sodium Channels Modulation by Beta Blockers
por: Chahine, Mohamed
Publicado: (2011)

The Use of Beta Blockers in Takotsubo Syndrome as Compared to Acute Coronary Syndrome
por: Kummer, Marvin, et al.
Publicado: (2020)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

The use of proton pump inhibitors decreases the risk of diabetes mellitus in patients with upper gastrointestinal disease: A population-based retrospective cohort study
por: Lin, Hsiu-Chen, et al.
Publicado: (2016)

SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
por: Kaplan, David E., et al.
Publicado: (2021)

Editorial: Emerging mechanistic insights of selective and Nonselective Autophagy in liver and gut diseases and their treatment strategies in the era of COVID-19
por: Alim Al-Bari, Md. Abdul, et al.
Publicado: (2023)

Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers
por: Bergh, Claes-Håkan, et al.
Publicado: (2010)

Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges
por: Zhao, Hong, et al.
Publicado: (2020)

Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
por: Lee, Seohyuk, et al.
Publicado: (2023)

Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study
por: Lapointe-Shaw, Lauren, et al.
Publicado: (2018)

Long-Term Effect of Non-Selective Beta-Blockers in Patients With Rheumatoid Arthritis After Myocardial Infarction—A Nationwide Cohort Study
por: Liu, Sheng-Fu, et al.
Publicado: (2021)

Hepatopulmonary syndrome is associated with the presence of hepatocellular carcinoma in patients with decompensated cirrhosis
por: Soulaidopoulos, Stergios, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_t7tkb05cf436cm3m6n0oj1thbc